-
Start Preamble
ACTION:
Notice of application.
DATES:
Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before August 30, 2017. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before August 30, 2017.
ADDRESSES:
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Start Printed Page 35547Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on March 7, 2017, R & D Systems, Inc., Bio-Techne, 614 McKinley Place NE., Minneapolis, Minnesota 55413 applied to be registered as an importer of the following basic classes of controlled substances:
Controlled substance Drug code Schedule Mephedrone (4-Methyl-N-methylcathinone) 1248 I JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) 7118 I CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) 7297 I Marihuana 7360 I Tetrahydrocannabinols 7370 I 4-Bromo-2,5-dimethoxyamphetamine 7391 I 3,4-Methylenedioxymethamphetamine 7405 I Dimethyltryptamine 7435 I Psilocyn 7438 I Pentobarbital 2270 II Phencyclidine 7471 II Cocaine 9041 II The company plans to import bulk active pharmaceutical controlled substances for distribution to its customers for analytical purposes.
In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic tetrahydrocannabinol. No other activity for these drug codes is authorized for this registration.
Start SignatureDated: July 24, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-16064 Filed 7-28-17; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 07/31/2017
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of application.
- Document Number:
- 2017-16064
- Dates:
- Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before August 30, 2017. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before August 30, 2017.
- Pages:
- 35546-35547 (2 pages)
- Docket Numbers:
- Docket No. DEA-392
- PDF File:
- 2017-16064.pdf